5 Biotech Stocks to Buy Now According to Srini Akkaraju and Michael Dybbs’ Samsara BioCapital

Page 5 of 5

1. Graphite Bio, Inc. (NASDAQ:GRPH)

Akkaraju and Dybbs’ Stake Value: $228,374,000
Percentage of Srini Akkaraju and Michael Dybbs’ 13F Portfolio: 28.19%
Number of Hedge Fund Holders: 22

Graphite Bio, Inc. (NASDAQ:GRPH), a clinical-stage gene-editing firm, is developing treatments for severe and life-threatening illnesses. The company was founded in 2017 and is placed first on the list of 15 biotech stocks to buy now according to Srini Akkaraju and Michael Dybbs’ Samsara BioCapital. 

On August 12, Graphite Bio, Inc. (NASDAQ:GRPH) announced earnings for the second quarter of 2021. It reported earnings per share of -$3.45, missing the estimates by $2.35. On July 20, Morgan Stanley analyst Jeffrey Hung initiated coverage of Graphite Bio, Inc. (NASDAQ:GRPH) with an “Overweight” rating and gave a price target of $35. 

Samsara BioCapital holds 7.43 million shares in Graphite Bio, Inc. (NASDAQdybbs:GRPH) worth over $228.37 million, representing 28.19% of their portfolio. The stock is a new arrival on Srini Akkaraju and Michael Dybbs’ portfolio. Insider Monkey’s data shows that 22 elite hedge funds held stakes in Graphite Bio, Inc. (NASDAQ:GRPH) in the second quarter.

You can also take a peek at 10 Best Biotech Stocks to Buy According to Cathie Wood and 11 Best Pharma and Biotech Stocks to Buy 

Page 5 of 5